Independent lines of evidence from in vivo and in vitro studies demonstrate that reduced SCD1 activity, and SFAs improve glucose and energy metabolism, adiposity, insulin responses, and adipose inflammation associated with obesity. This evidence concerns the gene SCD and obesity disorder.